MedComm

Scope & Guideline

Elevating Knowledge in Biochemistry and Beyond

Introduction

Welcome to your portal for understanding MedComm, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherWILEY
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationMEDCOMM / MedComm
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

MedComm focuses on advancing the understanding of human health and disease through innovative research methodologies, with a strong emphasis on molecular mechanisms, therapeutic strategies, and translational applications.
  1. Molecular Mechanisms of Disease:
    The journal emphasizes the exploration of molecular pathways involved in various diseases, including cancer, metabolic disorders, and autoimmune diseases, providing insights into their pathogenesis and potential therapeutic targets.
  2. Therapeutic Innovations:
    MedComm publishes studies on novel therapeutic strategies, including drug development, immunotherapy, and gene editing technologies, aimed at addressing unmet medical needs across a range of diseases.
  3. Translational Research:
    The journal highlights research that bridges the gap between laboratory findings and clinical applications, focusing on how basic science can inform clinical practice and improve patient outcomes.
  4. Emerging Technologies in Medicine:
    MedComm is at the forefront of publishing research related to cutting-edge technologies such as CRISPR, nanomedicine, and bioprinting, which are transforming the landscape of biomedical research and treatment.
  5. Interdisciplinary Approaches:
    The journal encourages interdisciplinary research that integrates fields such as genomics, proteomics, microbiome studies, and bioinformatics to provide comprehensive insights into health and disease.
Recent trends in MedComm's publications indicate a dynamic shift towards innovative research areas that reflect the evolving landscape of biomedical science.
  1. Cancer Immunotherapy:
    There is a significant increase in research related to cancer immunotherapy, including novel approaches like CAR-T cell therapy and immune checkpoint inhibitors, highlighting the importance of harnessing the immune system in cancer treatment.
  2. Precision Medicine and Genomics:
    The journal has seen a surge in publications focused on precision medicine, including genomic profiling and personalized treatment strategies, reflecting a growing emphasis on tailored healthcare solutions.
  3. Microbiome Research:
    Emerging studies investigating the role of the microbiome in health and disease are gaining traction, showcasing the interconnectedness of gut health and various systemic diseases.
  4. Regenerative Medicine:
    Research into regenerative medicine, including stem cell therapy and tissue engineering, is on the rise, emphasizing the potential for repairing or replacing damaged tissues and organs.
  5. Neuroinflammation and Neurodegenerative Diseases:
    An increasing focus on the mechanisms of neuroinflammation and its role in neurodegenerative diseases reflects a broader interest in understanding brain health and potential therapeutic targets.

Declining or Waning

While MedComm continues to expand its research horizons, certain themes have shown a decline in prominence or frequency of publication, reflecting shifting priorities within the field.
  1. Traditional Pharmaceutical Approaches:
    There has been a noticeable decrease in studies focusing solely on traditional pharmaceutical interventions, as the field shifts towards more innovative and personalized therapeutic strategies.
  2. Basic Descriptive Studies:
    The journal has seen fewer publications of basic descriptive studies that do not offer substantial insights into mechanisms or therapeutic implications, indicating a move towards more hypothesis-driven research.
  3. Single-Disease Focus:
    Research focusing exclusively on single diseases without considering comorbidities or broader health implications is becoming less common, as interdisciplinary approaches gain traction.
  4. Clinical Trials Reporting:
    The frequency of clinical trial reports has diminished, possibly due to the journal's emphasis on mechanistic and translational research over straightforward clinical outcomes.

Similar Journals

American Journal of Cancer Research

Fostering Breakthroughs in Cancer Research
Publisher: E-CENTURY PUBLISHING CORPISSN: 2156-6976Frequency: 12 issues/year

The American Journal of Cancer Research, with an ISSN of 2156-6976, is an esteemed publication in the field of oncology, dedicated to disseminating high-quality research in cancer biology, treatment advances, and molecular genetics. Published by E-CENTURY PUBLISHING CORP, this journal serves as a vital resource for oncologists, researchers, and students striving to advance their understanding of cancer mechanisms and therapeutic strategies. Though it has transitioned to a non-indexed status in Scopus since its coverage from 2012 to 2017, the journal continues to offer insightful contributions, situated within the 34th percentile in Medicine and Oncology and the 23rd percentile in Cancer Research. The open access availability empowers authors to share their knowledge widely, facilitating collaboration and progress in the battle against cancer. As the landscape of cancer research evolves, the American Journal of Cancer Research remains a significant platform for fostering dialogue and innovation in this critical area of healthcare.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Exploring the depths of disease mechanisms.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

FASEB BioAdvances

Elevating Understanding of Biological Processes Globally
Publisher: WILEYISSN: Frequency: 12 issues/year

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Molecular Biology Research Communications

Fostering innovation through peer-reviewed research.
Publisher: SHIRAZ UNIVISSN: 2322-181XFrequency: 4 issues/year

Molecular Biology Research Communications is a distinguished academic journal published by Shiraz University, focusing on the critical and rapidly evolving fields of biochemistry and molecular biology. With an ISSN of 2322-181X and an E-ISSN of 2345-2005, this journal serves as an essential platform for researchers, professionals, and students to disseminate significant findings that contribute to the advancement of knowledge in these disciplines. The journal, operating from Shiraz, Iran, is notable for its contributions from both local and international scholars, offering invaluable insights and fostering scientific collaboration. Although currently indexed in the Q4 quartile across its categories, the journal aims to enhance its impact and visibility in the field as it converges years of research from 2017 to 2024. While the open access option is not available, the journal's commitment to high-quality peer-reviewed research provides a respected avenue for publication.

Molecular Biomedicine

Connecting Research and Healthcare for a Healthier Tomorrow
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Transforming Knowledge in Biochemistry and Cell Biology
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Current Molecular Pharmacology

Pioneering Research for Tomorrow's Therapeutics
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Exploring Innovative Therapeutic Strategies
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

MOLECULAR CANCER RESEARCH

Elevating Understanding of Cancer at the Molecular Level
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

International Journal of Molecular and Cellular Medicine

Fostering Collaboration in Cutting-edge Molecular Research
Publisher: CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTERISSN: 2251-9637Frequency: 4 issues/year

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.